AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Can-Fite BioPharma Ltd.

Foreign Filer Report Nov 11, 2025

6713_rns_2025-11-10_1bc67003-3384-4092-9d12-88311bdbfc85.pdf

Foreign Filer Report

Open in Viewer

Opens in native device viewer

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934

For the Month of November 2025

001-36203 (Commission File Number)

CAN-FITE BIOPHARMA LTD.

(Exact name of Registrant as specified in its charter)

26 Ben Gurion Street Ramat Gan 5257346 Israel

(Address of principal executive offices)

Form 20-F ☒ Form 40-F ☐

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

On November 10, 2025, a Special General Meeting of Shareholders of Can-Fite BioPharma Ltd. (the "Company") approved each of the two proposals brought before the Company's shareholders at the meeting, in accordance with the majority required for each proposal. Each of those proposals was described in the Company's Notice and Proxy Statement with respect to the Company's Special General Meeting of Shareholders, dated October 3, 2025, attached as Exhibit 99.1 to the Company's Form 6-K that was furnished to the U.S. Securities and Exchange Commission on October 3, 2025.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Can-Fite BioPharma Ltd.

Date: November 10, 2025 By: /s/ Motti Farbstein

Motti Farbstein Chief Executive Officer and Chief Financial Officer

Talk to a Data Expert

Have a question? We'll get back to you promptly.